August 18, 2021 -- Biotechnology company Calidi Biotherapeutics has signed an exclusive license agreement with the University of Chicago (UChicago) and City of Hope for patents related to oncolytic virotherapy technology.
Specifically, the patents cover therapies using an oncolytic adenovirus in combination with a clinical-grade allogeneic neural stem cell line, according to Calidi. Scientists at City of Hope and the University of Chicago have used City of Hope's human neural stem cell line to selectively deliver an oncolytic adenovirus to tumor sites, Calidi said. They have received U.S. Food and Drug Administration approval to begin a phase I trial in recurrent glioma patients.
Patient trials are expected to begin in the first quarter of 2022. The license agreement transfers the investigational new drug application to Calidi for commercial development of a licensed product, according to the company. Calidi said it will have commercial exclusivity in using neural stem cells with the CRAd-pk-S-7 adenovirus for oncolytic virotherapy.
Financial details of the agreement were not disclosed.